Sanofi, GSK reach virus vaccine deals with US, EU | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Monday
June 02, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
MONDAY, JUNE 02, 2025
Sanofi, GSK reach virus vaccine deals with US, EU

Coronavirus chronicle

BSS/AFP
01 August, 2020, 10:50 am
Last modified: 01 August, 2020, 10:57 am

Related News

  • America’s cold shoulder to foreign students is worrying Asia
  • Bangladesh ready to buy more US cotton, oil to reduce trade gap: Yunus
  • US proposes 60-day ceasefire for Gaza, plan shows
  • Birth tourism not permitted on US visitor visa: US Embassy Dhaka
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj

Sanofi, GSK reach virus vaccine deals with US, EU

The firms aim to combine a Sanofi-developed antigen with GSK’s adjuvant technology, a substance that bolsters the immune response triggered by a vaccine

BSS/AFP
01 August, 2020, 10:50 am
Last modified: 01 August, 2020, 10:57 am
FILE PHOTO: The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020. REUTERS/Charles Platiau
FILE PHOTO: The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020. REUTERS/Charles Platiau

Pharma giants Sanofi and GSK will receive up to $2.1 billion from the US government for the development of a Covid-19 vaccine, the companies said Friday, as the world scrambles for an answer to the pandemic.

At the same time, the European Union said it had reached a deal with Sanofi for the supply of 300 million doses of a potential coronavirus vaccine.

The European Commission, the bloc's executive arm which negotiated the agreement, said it would allow all 27 EU member countries to purchase the vaccine once it was proven to be safe and effective.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The United States has identified a vaccine candidate under development by Sanofi and GSK for its "Operation Warp Speed," which aims to rapidly secure millions of doses.

The firms aim to combine a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK's adjuvant technology, a substance that bolsters the immune response triggered by a vaccine.

The American money will "help fund the development activities and secure scale-up of Sanofi's and GSK's manufacturing capabilities in the United States… resulting in a significant increase in capacity."

"The US government will provide up to $2.1 billion, more than half of which is to support further development of the vaccine, including clinical trials, with the remainder used for manufacturing scale-up and delivery of an initial 100 million doses," the companies said.

"The US government has a further option for the supply of an additional 500 million doses longer term," they added.

The United States is the country the worst hit by the coronavirus outbreak, with over 150,000 deaths out of the global toll of more than 667,000.

Europe meanwhile has recorded nearly 210,000 deaths from 3.2 million cases, and with infections rising again in several countries there are fears a "second wave" of the pandemic could be on the way.

Sanofi, based in France, and GSK of Britain said clinical trials of their vaccine should start in September, with a Phase 3 study under way by the end of the year.

Billion doses per year

"If the data are positive, the companies can request US regulatory approval in the first half of 2021. In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant to produce up to one billion doses per year globally," they said.

US Health and Human Services Secretary Alex Azar said the portfolio of vaccines being assembled under Operation Warp Speed "increases the odds that we will have at least one safe, effective vaccine as soon as the end of this year."

The United States has already committed some $6 billion since March to vaccine projects with pharma giants such as Johnson & Johnson, Pfizer and AstraZeneca.

The latest investment holds the "potential to bring hundreds of millions of safe and effective doses to the American people," Azar said in the statement.

The companies said discussions were also under way with the European Commission and other governments "to ensure global access to a novel coronavirus vaccine."

The partners intended to supply "a significant portion of total worldwide available supply capacity" in 2021 and 2022 to an initiative seeking to ensure equitable global access to Covid-19 tests, treatments and vaccines.

'Global public good'

Sanofi CEO Paul Hudson drew the ire of French officials in May when he suggested any Covid-19 vaccine would be offered first to the US government because it had been investing in its development.

Under pressure, he later indicated it would be available to everyone at the same time.

Other countries too, have been investing in a vaccine against the novel coronavirus, with Sanofi and GSK announcing a deal with Britain on Wednesday for 60 million doses.

Laboratories need the money to accelerate the early stages of vaccine development and prepare production units without fearing they will be left out of pocket if the candidate drugs fail.

In turn, governments seek to ensure they will get the first doses if the vaccines do work.

Such deals have drawn criticism for leaving behind poor countries who do not have the cash to conclude such contracts.

Earlier this month, the UN Human Rights Council stressed the importance of "equitable and unhindered access" to diagnostics, treatments and vaccines, and said any vaccine developed against Covid-19 should be considered a "global public good".

Top News

Sanofi / GSK / Coronavirus Vaccine / Vaccine / USA / EU

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Illustration: TBS
    Inflation expected to drop below 8% in June: Finance adviser
  • Infograph: TBS
    What will be your tax rate?
  • Saleh Uddin Ahmed. Sketch: TBS
    Ensuring food security top priority for govt, says Finance adviser in budget speech

MOST VIEWED

  • Infographic: TBS
    Govt targets Dec opening of Dhaka airport's 3rd terminal but Japanese consortium wants 2 more months
  • Infograph: TBS
    Low imports, low confidence, low growth: Is Bangladesh in a slow-burning crisis?
  • Representational image. Photo: Reuters
    Remittance hits second-highest monthly record of $2.97b in May ahead of Eid
  • Budget may offer major tax breaks for capital market
    Budget may offer major tax breaks for capital market
  • Teesta River overflowing at one of its gates on 1 June 2025. Photo: UNB
    44 gates opened as water levels in Teesta rise
  • Infographic: TBS
    Jobs drying up as private sector struggles to survive

Related News

  • America’s cold shoulder to foreign students is worrying Asia
  • Bangladesh ready to buy more US cotton, oil to reduce trade gap: Yunus
  • US proposes 60-day ceasefire for Gaza, plan shows
  • Birth tourism not permitted on US visitor visa: US Embassy Dhaka
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj

Features

Sketch: TBS

Budget FY26: What corporate Bangladesh expects

6h | Budget
The customers in super shops are carrying their purchases in alternative bags or free paper bags. Photo: Mehedi Hasan

Super shops leading the way in polythene ban implementation

5h | Panorama
Photo: Collected

Slice, store, sizzle: Kitchen must-haves for Eid-ul-Adha 2025

1d | Brands
The wide fenders, iconic hood scoop and unmistakable spoiler are not just cosmetic; they symbolise a machine built to grip dirt, asphalt and hearts alike. PHOTO: Akif Hamid

Resurrecting the Hawkeye: A Subaru WRX STI rebuild

1d | Wheels

More Videos from TBS

Bangladeshi agent of online gambling site arrested in Jhenaidah

Bangladeshi agent of online gambling site arrested in Jhenaidah

14m | TBS Stories
Bus-Truck-Taxi Advance Tax is Increasing; What Will Be the Impact?

Bus-Truck-Taxi Advance Tax is Increasing; What Will Be the Impact?

24m | Others
Primary Education Faces Budget Cuts as Secondary, Madrasa Allotments Rise

Primary Education Faces Budget Cuts as Secondary, Madrasa Allotments Rise

39m | Others
A budget meant to fix, not to dream

A budget meant to fix, not to dream

1h | TBS Insight
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net